Member Info for Hedgehog100

Destiny And SporeGen Back Nasal Spray Over Vaccine To Tackle COVID-19

Easy To Use And Produce

09 Sep 2020 INTERVIEWS

by kevin.grogan@informa.com

... Destiny and SporeGen have been awarded a grant of £800,000 from Innovate UK to fund the majority of the £1m ($1.3m) needed for the initial SPOR-COV program. The preclinical work will be undertaken in collaboration with the University of Liverpool, while manufacturing and formulation development will be carried out by Huro, based in Vietnam.

The aim is to start human clinical studies in the next 18 months but Cutting noted that the partners "will have to make a decision about the best way to move forward, " either taking the classic (and lengthy) drug development route or adopting a medical food intervention approach.

Destiny CEO Neil Clark told Scrip, "We're pragmatic about how the product could be delivered, and would have no problem going down the regulated food medicine route or the classic drug development route. Once we produce the data, it will be very interesting to see how the regulatory environment develops. There's been a lot of amazing rapid approvals of studies in the vaccine eld so if we can deliver a strong data package, are we going to get similar support? The prole of this product is much safer than the vaccines."

Clark stressed that "we're both high-quality R&D companies, based on validated science and we're well funded now to kick on. I think a year from now, potentially it will be very interesting to see where we're going with the data set."

Cutting concluded by saying that "there are long-term benets to having a simple solution yet we live in a world where everything has to be sophisticated. It's one of the big problems with science. If I were to speak to [UK prime minister] Boris Johnson and show him a simple approach or very sophisticated approach, he'd focus on the sophisticated approach. It is human nature."

The deal met with approval from Equity Development analyst Andy Smith who issued a note saying that Destiny "have always had a microbiome tilt with their most advanced product, topical XF-73 (exepornium chloride), being developed for the prevention of post-operative infections." With the SporeGen deal, "they have taken this even further to encompass the two hot-button issues in anti-infectives: the microbiome and coronavirus infections."

He added, "This positive development plays to Destiny’s strengths in topical (nasal) administration,
preventative indications, as well as the cost-effective management of its earlier-stage pipeline…the
development of SporeGen’s technology as a preventative therapy for COVID-19 has many advantages
over traditional vaccines."

https://www.destinypharma.com/2020/09/10/10-sep-2020-scrip-article-destiny-pharma-and-sporegen-back-nasal-spray-over-vaccine-to-tackle-covid-19/

Destiny And SporeGen Back Nasal Spray Over Vaccine To Tackle COVID-19

Easy To Use And Produce

09 Sep 2020 INTERVIEWS

by kevin.grogan@informa.com

Executive Summary
The SPOR-COV prophylactic approach targets the innate immune system and has the potential to develop COVID-19 protection within a few days of treatment, the partners tell Scrip.

The search for a vaccine dominates the headlines but two UK biotechs are taking a prophylactic approach to develop a nasal spray that targets the innate immune system, which has the potential to develop COVID-19 protection within a few days of treatment.

Antimicrobial specialist Destiny Pharma plc has teamed up with SporeGen Ltd. to co develop its SPOR-COV product which contains a proprietary formulation of Bacillus bacteria that will be administered nasally via a spray. Unlike traditional vaccination, SPOR COV focuses on innate immunity and having provided 100% protection in preclinical models of inuenza virus, the companies believe this could also apply to coronavirus infection.

SporeGen CEO Simon Cutting told Scrip that the vaccines being developed for COVID 19 are injectable "but you acquire this disease in your respiratory tract and normally you vaccinate at the sites where you want to develop protection, which is the mucosal route. My prediction is that the vaccines being developed at the
moment probably will protect you from death and will have some level of protection, but they won't protect you from being colonized. If people are colonized by the virus, they can then spread it to other people, so vaccines are unlikely to prevent the disease from disseminating across the world."

He noted, "In the absence of seeing any data at this moment in time, no one really knows what's going to happen. Our approach is like taking an amplier and switching up the frequency like in the movie Spinal Tap where if you boost immunity, you're more protected." Cutting said elderly people "seem to be most susceptible to this disease and they are more immune compromised, so maybe you just need a simple solution for boosting immunity and that's something we've been working on."

COVID-19 is the fourth pandemic in 20 years "and there's a high probability that in the future, we will have future pandemics," he noted, saying that "we need something that does not require cold-chain refrigeration, could be manufactured very simply and could be stockpiled." While the science behind the project is sophisticated, "we have a very pragmatic and very simple approach, which we already know works for pandemic u."

SPOR-COV "is very much a disruptive technology, it's rather like Uber," Cutting said. "This is a pandemic and we need an approach that works now." ...

https://www.destinypharma.com/2020/09/10/10-sep-2020-scrip-article-destiny-pharma-and-sporegen-back-nasal-spray-over-vaccine-to-tackle-covid-19/

Thanks TruthCaller.

Not long to wait I would think.

Good luck to all genuine holders.

This is a post that I posted on the LSE IQAI board in June of last year, when I recommended IQAI as a strong buy at 1.15p.
By the end of September IQAI had risen over 1,000%. -

Hedgehog100 Posts: 967 Price: 1.15 Strong Buy

Trevor Brown Stellar Track Record 7 Jun '19

"Trevor Brown has been subjected to some libellous persecution from a troll with a grudge.

So let's "seek truth from facts" and examine his record shall we: the share price performance during his two previous listed directorships prior to here. -

1. ADVANCED ONCOTHERAPY (AVO) (formerly CareCapital): 28.6.12 - 30.8.13.

Share price rise from approx. 25p to approx. 92p: GAIN OF C. 268%.

2. FEEDBACK (FDBK): 13.1.14 - 8.6.17

Share price rise from approx. 0.85p to approx. 3.75p: GAIN OF C. 341%.

= AVERAGE INCREASE OF c. 304.5%.

In summary, on the key metric of share price performance, Trevor Brown has really delivered the goods: an on average QUADRUPLING of these two share prices.

(I've posted fuller info. in post 245 on the ADVFN IQAI thread.)"

https://www.lse.co.uk/ShareChat.asp?ShareTicker=IQAI&share=Iq-ai-Ltd&page=201

RMS is far closer to reporting significant revenues than many other COVID-19 stocks that have multibagged, but with a far lower valuation.

And the best way to make money in investment is to position yourself ahead of coming contracts, rather then scrambling to buy in afterwards at a much higher share price.

The old AERO days have gone, and are now irrelevant.

This is in effect now a new share with new management.

And there's no penny share manager that I would prefer to back than Trevor Brown.

His fantastic business and investment track record is simply stunning, combined with a rare level of integrity which means that he can be trusted implicitly.

Rick & Lawrmyer,

Contracts have indeed been signed and RNSed and more should be announced in the near term, as per the following RMS updates:

8th Apr 2020 7:00 am RNS Cloudveil and GyroMetric Update

"Cloudveil reports unprecedented level of interest in its crisis management services

GyroMetric secures an order and continues production

Remote Monitored Systems plc is pleased to report the following updates by Cloudveil Limited ("Cloudveil"), which is wholly owned by the Group, and Gyrometric Limited ("GyroMetric"), the Group's 58% owned subsidiary. Cloudveil has seen a surge in demand and has secured an order whilst GyroMetric has maintained production and secured an order with a significant customer. The full updates are set out below. ... "

https://www.lse.co.uk/rns/RMS/cloudveil-and-gyrometric-update-8ewa2wijdcntpox.html

29th Jun 2020 7:00 am RNS Final Results for the Year to 31 December 2019

" ... Outlook

The Group will now continue to make progress across all elements of its business.

GyroMetric, in which the Company owns a 58% interest, though initially experiencing delays in both sales and installations as a result of the Covid-19 pandemic, now expects that a number of installations and trials including those at Tarmac and Clarke Energy will proceed as imminent maintenance windows arise at client sites.

Cloudveil Limited ("Cloudveil"), the intelligence services and security risk management business acquired in September 2019, whilst also suffering delays and changes in scopes of work caused by the pandemic, has also experienced an unprecedented level of enquiries for its services from a variety of blue chip companies and other private and public bodies in the UK and Europe, and is at an advanced stage of negotiation of commercial terms with a number of these potential customers. As a consequence, Cloudveil is forecasting significant growth, including through sales of IRIS, over the next eighteen months, including contracts expected to start in the forthcoming quarter.

Your Board, substantial owners of the company's shares, is determined to deliver near term value to shareholders through exploiting opportunities we have created over recent months. As the markets in which we operate return to normality, we anticipate issuing regular updates on our progress. ..."

https://www.lse.co.uk/rns/RMS/final-results-for-the-year-to-31-december-2019-fwxxfauzk9k243j.html

10th Sep 2020 7:00 am RNS Notice of Results

Notice of Interim Results

Brighton, United Kingdom - 10 September 2020 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR), will announce its financial results for the six months ended 30 June 2020 on Thursday, 17 September 2020.

A webcast for analysts will take place at 09:30am BST.

https://www.lse.co.uk/rns/DEST/notice-of-results-q80n0verdrrq78a.html

Lawrmyer,

I think your views are coloured by the old AERO days, before Trevor Brown completely reinvented this company.

Trevor Brown has a very successful track record as a businessman and investor, and is very trustworthy.

And the recent acquisition is a sign of that:

17th Jul 2020 7:00 am RNS Potential Acquisition
"The Board of Remote Monitored Systems plc is pleased to announce that it has entered into an exclusivity arrangement and agreed outline non-binding heads of terms in respect of a potential acquisition of a company that operates in the fast growing medtech and biosecurity sectors. ... "
https://www.lse.co.uk/rns/RMS/potential-acquisition-u4tjng0yeqowsz6.html

21st Aug 2020 4:26 pm RNS Conditional Agreement to Acquire 100% of P2F
"RMS (AIM: RMS) is pleased to announce that further to the announcement of 17 July 2020, it has signed a binding Share Purchase Agreement for the acquisition of 100% of the share capital of Pharm2Farm Limited ("P2F") (the "Acquisition"). ..."
https://www.lse.co.uk/rns/RMS/conditional-agreement-to-acquire-100-of-p2f-pwilvw67azgmujn.html

RMS now has multiple cracking growth plays, with very positive newsflow coming on multiple fronts, with a good-looking chart, but still very lowly-valued.

What's not to like?!

"Technical Analysis for DEST - Destiny Pharma Plc"

"Grade Last Price % Change Price Change
grade A 57.3 -2.88% -1.70"

"ADX Long Term Intermediate Term Short Term
Very Strong Up Up Up"

https://lse.swingtradebot.com/equities/DEST:LSE

"Destiny Pharma PLC (DEST)"
"57.30 -1.70 -2.88%"

"DEST Technical Analysis"

"Summary:
STRONG BUY
Moving Averages: BUY Buy (12) Sell (0)
Technical Indicators: STRONG BUY Buy (8) Sell (0)"

https://uk.investing.com/equities/destiny-pharma-technical

"Technical Analysis for RMS - Remote Monitored Systems Plc"

"ADX Long Term Intermediate Term Short Term
Very Strong Up Up Up"

https://lse.swingtradebot.com/equities/RMS:LSE

"RMSR Technical Analysis"

"Summary:
STRONG BUY
Moving Averages: BUY Buy (11) Sell (1)
Technical Indicators: STRONG BUY Buy (6) Sell (2)"

https://uk.investing.com/equities/strat-aero-plc-technical

"5. Date on which the threshold was crossed or reachedvi:
19/08/2020"

As Thomas Anderson isn't an ORM director he's free to buy ORM shares in the current close period before ORM's interim results, due by the end of September.

Provided of course that he isn't in possession of any inside information, which presumably he isn't.

DEST is forecasting peak US sales for its XF-73 drug of $US 1 billion.

In contrast, DEST's current market cap. at 45.1p is just £19.78 million.

3rd Mar 2020 7:00 am RNS Clinical and Business Update

" ... The Company's ongoing Phase 2b clinical trial of its lead asset, XF-73 (exeporfinium chloride) nasal gel, is testing XF-73 as a novel drug for the prevention of post-surgical infections caused by Staphylococcus aureus (SA), including the superbug variant methicillin-resistant S. aureus (MRSA). US, EU and WHO surgical guidelines are recommending this type of treatment to tackle nasal SA/MRSA bacterial carriage in all high risk surgeries and the Company forecast peak US sales of $US 1 billion driven by the appropriate use of XF-73 in millions of eligible surgical procedures. ..."

https://www.lse.co.uk/rns/DEST/clinical-and-business-update-dked0g479qdnhmx.html

EDITORS' PICK|3,588 views|Aug 4, 2020,07:00am EDT

Could Drug-Resistant Bacteria Cause The Next Pandemic?

Louis Metzger IV Contributor
Healthcare
I am an infectious disease biochemist and entrepreneur.

... Aided by modern humans' mobility and by climate change, bacterial pathogens endanger everyone's health. They are legion, varied, and constantly mutating. ...

The germs of some of history's worst pandemics, bacteria still imperil human health on a massive scale. Tuberculosis, caused by the bacterium Mycobacterium tuberculosis, has afflicted humanity for millennia. Twenty-five percent of the world's population may carry a latent form of the disease. Killing 1.5 million annually, it is the leading cause of infectious disease death. Strains of Mycobacterium tuberculosis have mutated to become resistant to many or all antibacterial drugs.

The aptly-named Yersinia pestis caused the Bubonic plague, which ravaged Eurasia and Africa, periodically flaring into catastrophic pandemics between the 6th and 19th centuries CE. It remains in animals and still spreads to humans in places as diverse as Mongolia, where it appeared in May, and New Mexico, where it surfaced last week. ...

Bacteria have developed ways to pump antibacterial drugs out of themselves, destroy antibiotics that successfully penetrate them, and otherwise evade antimicrobial molecules. Bacteria are capable of exchanging and collecting genes that encode these drug resistance and virulence mechanisms, thereby acquiring, in some cases, imperviousness to all antibiotics previously used to treat them. Unprecedented human travel and globalization have enabled bacteria from one place to take hold in another. ...

Between 1990 and 2019, 78% of major drug companies have reduced or eliminated antibiotic research. Some startups pursuing antibacterials have pivoted away from infectious disease research to survive. A genuinely novel class of antibacterial drugs, dissimilar in chemical structure to current types of antibiotics, has not been developed in more than three decades.

... To assist small companies in developing antibacterial drugs, a consortium of pharmaceutical companies recently established the AMR Action Fund. This entity plans to spend $1 billion to help bring two to four new antibiotics to the clinic by 2030. Moreover, it intends to build an alliance of stakeholders to encourage governments to create conditions favorable to sustainable antibacterial discovery and development.

A "Manhattan Project" to Fight Antibiotic-Resistant Bacteria

Organizations like CARB-X and the AMR Action Fund provide critical assistance in the battle against bacterial pathogens. Given that bringing a single antibiotic from concept to clinic costs $1 billion, and given the need for many new drugs, we must make much more significant investments. ...

https://www.forbes.com/sites/louismetzgeriv/2020/08/04/could-drug-resistant-bacteria-cause-the-next-pandemic/#2dfaec0427d8

"Thanks Schaden - words out of my mouth...."

Perhaps it's even the same mouth? I.e. Jezabel is also posting as Schaden on this site?

Very similar styles of writing, and very similar views.

And posters like this do seem to like talking to themselves, and supporting themselves.

This would be a clear breach of LSE's terms & conditions, and would also be criminal.

Certainly something for the Financial Conduct Authority.

Because, Agnes, RMS has stated very clearly that there is positive news coming here, on multiple fronts.

"I don't know who or what you're talking about - but I do know what market abuse is: ..."

Schaden,

You obviously can't read very well then, because I very clearly stated that I was talking about the poster Jezabel on LSE, who posts as Pilotov on ADVFN.

Jezabel-Pilotov is not denying this, although he was trying to pose as someone different here, having requested on ADVFN that we filter each other, to give a dishonest impression of there being more bear posters on RMS than there actually is.

Your quote on market abuse isn't a definition, let alone an exhaustive definition: it is merely giving one example of what may constitute it, i.e. insider dealing.

A different type of market abuse is where somebody is wilfully posting dishonestly for financial gain: they may have no insider information, but they would certainly be committing market abuse.

Here's some of LSE's views on market abuse, which say nothing about insider dealing:
https://www.lse.co.uk/chat/general/help-and-feedback/market-abuse-F851CD7E-D2C7-4AF2-BB8F-C1B5EF721CE9.html

If someone (e.g. Jezabel-Pilotov) is posting on one share only, and no others, always negatively, quite often, on multiple sites, with different user names, over an extended period, and with no explanation, then there is no way that they are a genuine poster. Anyone who thinks otherwise is being very naive.

A poster like Jezabel-Pilotov will never give RMS any real credit for anything, or to Trevor Brown for the excellent work he's been doing here.

11th Aug 2020 7:00 am RNS Positive interim safety review of XF-73 phase 2b

Positive interim safety review of Phase 2b clinical trial of lead asset XF-73 in the prevention of post-surgical bacterial infections

Brighton, United Kingdom - 11 August 2020 - Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel treatments for hospital infections that address the global challenge of antimicrobial resistance (AMR), announces a positive interim safety review has been completed by an Independent Data Monitoring Committee (IDMC) of the Company's ongoing Phase 2b study of its lead asset XF-73 in the prevention of post-surgical bacterial infections.

Further to the announcement on 27 July 2020 detailing a US Food and Drug Administration approved clinical protocol amendment to the Phase 2b study, the IDMC has reviewed safety data from the first 75 cardiac surgery patients who have completed study treatment. Adverse event data, including safety laboratory results, incidence of post-operative infections, ear, nose, and throat examinations, as well as sense of smell tests were reviewed by the IDMC. Based on their evaluation, the IDMC has recommended that the study can continue without any modifications to the protocol. Recruitment into the study remains on track to complete by the end of 2020.

Neil Clark, Chief Executive Officer of Destiny Pharma, commented:

"We are very pleased the IDMC has concluded that there are no safety concerns in the patients treated in the Phase 2b study to date and that the study can continue as planned. This is consistent with our previous experience of testing XF-73 in several clinical studies. We believe XF-73 nasal gel has the potential to become a well-tolerated, novel and effective treatment for the prevention of post-surgical Staphylococcal infections and represents a significant commercial opportunity. We are now two thirds of the way through the study and look forward to completing recruitment by the end of 2020."

The ongoing Phase 2b trial is a multi-centre, randomised, blinded, placebo-controlled study of multiple applications of a single concentration of XF-73 nasal gel to assess the microbiological effect of XF-73 on commensal Staphylococcal aureus nasal carriage in 125 patients scheduled for surgical procedures deemed to be at high risk of post-operative Staphylococcal aureus infection.

The Phase 2b study design is closely related to the successful 2016 clinical trial, which was funded by the National Institute of Allergy and Infectious Disease (part of the US National Institute of Health) and demonstrated the clinical efficacy of XF-73 versus placebo in reducing nasal Staphylococcus aureus carriage in healthy volunteers.

https://www.lse.co.uk/rns/DEST/positive-interim-safety-review-of-xf-73-phase-2b-94m1stut92x5cwa.html

Sorry, this is the correct link:

https://uk.investing.com/equities/polarean-imaging-plc-technical

The SwingTradeBot site is also bullish on POLX, but hasn't been updated since 29th. July so is based on a 31p share price.